Cancer drug start-up Peloton raises $18M

Peloton Therapeutics, a Dallas, Texas-based early-stage small-molecule cancer drug company, has come out of stealth mode. It has announced that it raised $18 million in a series A financing for development on three in-licensed programmes from the University of Texas Southwestern Medical Center. This follows an $11 million grant from cancer research funds provided by the state of Texas.